Table 1 Characteristics of the patients.

From: Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy

 

Overall

Control

Anemia

P value

(N = 10,923)

(N = 2428)

(N = 8495)

Age, years

63.4 ± 16.2

59.7 ± 16.8

64.4 ± 15.8

 < 0.001

Sex, male

6567 (60.1)

1778 (73.2)

4789 (56.4)

 < 0.001

Tertiary

5658 (51.8)

1114 (45.9)

4544 (53.5)

 < 0.001

Comorbidities

Charlson index

1.9 (1.9)

1.2 (1.6)

2.0 (1.9)

 < 0.001

 Chronic liver disease

1372 (12.6)

281 (11.6)

1091 (12.8)

0.1

 Diabetes Mellitus

3337 (30.6)

800 (32.9)

2537 (29.9)

0.004

 Chronic Kidney Disease

2646 (24.2)

246 (10.1)

2400 (28.3)

 < 0.001

 Cancer

1554 (14.2)

166 (6.8)

1388 (16.3)

 < 0.001

 Hypertension

2598 (23.8)

557 (22.9)

2041 (24.0)

0.27

 Septic shock

5758 (52.7)

961 (39.6)

4797 (56.5)

 < 0.001

Treatment

 CRRT duration, days

6.0 ± 4.2

4.2 ± 1.5

6.5 ± 4.5

 < 0.001

 Mechanical ventilation

4718 (43.2)

775 (31.9)

3943 (46.4)

 < 0.001

  1. Continuous variables and categorical variables are presented as means ± standard deviations and numbers (percentages), respectively.
  2. Charlson comorbidity was defined as the presence of disease within 1 year prior to admission.
  3. CRRT continuous renal replacement therapy, SD standard deviation.
Back to article page